Evommune, Inc.
EVMN
$24.09
-$0.94-3.76%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | 85.71% | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 85.71% | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | 85.71% | -- | -- | -- | |
| SG&A Expenses | 56.85% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 22.15% | -- | -- | -- | |
| Operating Income | -15.79% | -- | -- | -- | |
| Income Before Tax | -3.09% | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -3.09% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -3.09% | -- | -- | -- | |
| EBIT | -15.79% | -- | -- | -- | |
| EBITDA | -15.94% | -- | -- | -- | |
| EPS Basic | 38.23% | -- | -- | -- | |
| Normalized Basic EPS | 36.85% | -- | -- | -- | |
| EPS Diluted | 38.23% | -- | -- | -- | |
| Normalized Diluted EPS | 36.85% | -- | -- | -- | |
| Average Basic Shares Outstanding | 304.39% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 304.39% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |